-
Tankyrase Inhibitors Suppress HCC via Hippo Signaling
2026-09-11
Jia et al. show that the tankyrase inhibitors XAV-939 and G007-LK restrain hepatocellular carcinoma cell growth through a mechanism involving AMOTL1/2 stabilization, reduced YAP activity, and suppression of Hippo-pathway transcriptional output. The study expands tankyrase biology beyond canonical Wnt regulation and provides a rationale for investigating pathway combinations in HCC models.
-
Trypsin-Responsive Nanomedicine for Acute Pancreatitis
2026-09-10
The reference study develops a mesoporous organosilica nanoparticle that combines mesenchymal stem cell membrane camouflage, pancreatic acinar cell targeting, and trypsin-triggered BAPTA-AM release. In a mouse model of acute pancreatitis, this design reduced calcium overload and pancreatic injury while improving enzyme profiles and survival, although substantial translational questions remain.
-
DMH1: Selective ALK2 Inhibitor for BMP Research
2026-09-10
DMH1 is a selective ALK2 inhibitor that suppresses BMP-driven Smad1/5/8 signaling and Id gene expression. DMH-1 supports mechanistic non-small cell lung cancer research, but its IC50 is assay-specific and its activity in pancreatic ductal organoids remains unestablished.
-
EdU Imaging Kits (HF594) for PNI Research
2026-09-09
EdU Imaging Kits (HF594) enable antibody-free measurement of S-phase DNA synthesis in pancreatic cancer–Schwann cell models. The workflow complements invasion and dedifferentiation assays by showing whether PTGES–PGE2 perturbation changes proliferative behavior in 2D, 3D, microscopy, or flow cytometry experiments.
-
SU6656 in hiPSC Platelet Engineering
2026-09-09
SU6656 is a Src tyrosine kinases inhibitor with a distinctive role in megakaryocyte polyploidization research. This article explains how to interpret its biology within an optimized hiPSC-to-platelet workflow without confusing exploratory perturbation with validated process performance.
-
Optimizing hiPSC-Derived Platelet Production
2026-09-08
This 2026 study develops an optimized differentiation scheme that combines higher embryoid-body input, human platelet lysate, cytokine-replacing small molecules, and enhanced megakaryocyte maturation. The resulting workflow shortens production, improves functional platelet output, and reduces reported costs, while also clarifying that SU6656 itself was not directly validated as the driver of the headline yield.
-
JPJDXZF, BIRC5, and Hippo Signalling in HCC
2026-09-08
This 2026 study combines network pharmacology with cell, organoid, and animal experiments to investigate how Jianpi Jiedu Xiaozheng Fang may suppress hepatocellular carcinoma progression. Its central mechanistic signal is the association between BIRC5, Hippo pathway activity, and reduced tumour proliferation, migration, and growth, although further causal and clinical validation is needed.
-
ABT-199: Precision Lessons for Translational Apoptosis
2026-09-07
ABT-199, also known as Venetoclax or GDC-0199, offers a precise way to interrogate BCL-2 dependence while exposing the limits of single-target apoptosis strategies. This thought-leadership perspective connects molecular selectivity, apoptosis assay design, and combination logic for non-Hodgkin lymphoma research and acute myelogenous leukemia research.
-
Epinephrine in Local Anesthesia: Concentration and Risk
2026-09-07
Cassidy, Phero, and Grau’s review explains how vasoconstrictors improve local-anesthetic duration, hemostasis, and neural blockade while also producing dose- and route-dependent systemic effects. Its central practical conclusion is that 1:200,000 epinephrine can often provide effective anesthesia with less unnecessary adrenergic exposure than stronger concentrations.
-
Naloxone Hydrochloride: A Causal Probe
2026-09-05
Naloxone hydrochloride is more than an emergency antagonist: it is a reversible probe for separating opioid receptor signaling from receptor-independent biology. This article connects withdrawal-anxiety circuitry, neural stem cell proliferation modulation, and assay design while highlighting how to interpret antagonist data responsibly.
-
PEDV Hijacks IMPDH-Dependent Nucleotide Biosynthesis
2026-09-04
Zhou and colleagues identify IMPDH2 and guanine nucleotide biosynthesis as host dependencies for porcine epidemic diarrhea virus (PEDV) replication. By combining comparative metabolomics, IMPDH2 knockdown, and merimepodib inhibition, the study provides a mechanistic basis for host-directed antiviral research while highlighting cell-type-specific metabolic responses.
-
Acetoacetic Acid Sodium Salt: Assay Workflows
2026-09-04
Build reproducible ketone-body experiments with a water-compatible sodium acetoacetate source, from stock preparation through metabolic readouts. Practical dosing, matrix controls, and orthogonal QC help distinguish true energy-metabolism effects from solubility, pH, or handling artifacts.
-
PDK4 Inhibitors: Findings from an Anthraquinone Series
2026-09-03
The reference study used anthraquinone hit optimization to identify compound 8c, an allosteric PDK4 inhibitor with strong biochemical activity and encouraging metabolic, allergic-disease, and anticancer findings. Its combination of enzyme assays, pharmacokinetic evaluation, mouse models, and docking provides a useful preclinical framework for developing PDK4-directed therapies, while leaving important questions about selectivity, durability, and clinical translation unresolved.
-
G007-LK Tankyrase 1/2 Inhibitor Guide
2026-09-03
G007-LK is a selective tankyrase 1/2 inhibitor for mechanistic studies of Wnt/β-catenin signaling, β-catenin turnover, and cancer biology. Its reported nanomolar biochemical activity and preclinical activity in APC-mutant colorectal and hepatocellular carcinoma models support use as a research tool, not as evidence of clinical efficacy.
-
Fumagillin Against Azumiobodo hoyamushi
2026-09-02
The reference study compared 20 antiprotozoal, antimicrobial, oxidizing, and halogen-based compounds against Azumiobodo hoyamushi, identifying Fumagillin as a moderately active agent in vitro rather than one of the most potent treatments. Its paired in vitro–in vivo design showed that formalin and chlorine dioxide reduced parasite burdens in experimentally infected ascidians, providing a practical framework for evaluating disinfection strategies in aquaculture.